Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer

Torahiko Nakashima, Yuichiro Kuratomi, Tomoya Yamamoto, Muneyuki Masuda, Naoya Hirakawa, Kazumasa Nakamura, Yoshiyuki Shioyama, Toshiro Umezaki, Shizuo Komune

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The triple combination of 5-fluorouracil (5-FU), vitamin A and radiation (FAR therapy) has been effectively used to treat head and neck cancer. The biological anti-tumor effect of 5-FU depends on the activity of its metabolizing enzyme, dihydropyrimidine dehydrogenase (DPD). TS-1 is a novel oral DPD inhibitory fluoropyrimidine (DIF). To improve the anti-tumor effect of FAR therapy, we have applied TS-1 in place of 5-FU injection in the combination of Vitamin A and radiation (TAR therapy). In this study, we have examined the appropriate duration of TS-1 medication and the clinical efficacy and safety of TAR therapy. TS-1 was administered orally at a dose of 65 mg/m2 twice a day. Vitamin A (Retinol Palmitate: 50,000 U/day) was administered intra-musculary on each day of radiation. Radiation was given (1.5-2 Gy/day: 5 days/week) for 30-40 Gy. The levels were divided according to the length of TS-1 application as follows: level 1, 2 weeks; level 2, 3 weeks; level 4, 4 weeks. Grade 4 toxicity of anorexia was observed in one case of level 3. We decided that level 2 (3 weeks of TS-1 administration) was the appropriate length of TS-1 application. TAR therapy is a useful concurrent chemo-radiotherapy which might improve the response rate and QOL of patients with HNSCC.

Original languageEnglish
Pages (from-to)803-807
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume32
Issue number6
Publication statusPublished - Jan 1 2005

Fingerprint

Head and Neck Neoplasms
Vitamin A
Cohort Studies
Radiotherapy
Dihydrouracil Dehydrogenase (NADP)
Fluorouracil
Therapeutics
Radiation
Anorexia
titanium silicide
Neoplasms
Safety
Injections
Enzymes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakashima, T., Kuratomi, Y., Yamamoto, T., Masuda, M., Hirakawa, N., Nakamura, K., ... Komune, S. (2005). Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 32(6), 803-807.

Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer. / Nakashima, Torahiko; Kuratomi, Yuichiro; Yamamoto, Tomoya; Masuda, Muneyuki; Hirakawa, Naoya; Nakamura, Kazumasa; Shioyama, Yoshiyuki; Umezaki, Toshiro; Komune, Shizuo.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 32, No. 6, 01.01.2005, p. 803-807.

Research output: Contribution to journalArticle

Nakashima, T, Kuratomi, Y, Yamamoto, T, Masuda, M, Hirakawa, N, Nakamura, K, Shioyama, Y, Umezaki, T & Komune, S 2005, 'Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 32, no. 6, pp. 803-807.
Nakashima T, Kuratomi Y, Yamamoto T, Masuda M, Hirakawa N, Nakamura K et al. Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer. Gan to kagaku ryoho. Cancer & chemotherapy. 2005 Jan 1;32(6):803-807.
Nakashima, Torahiko ; Kuratomi, Yuichiro ; Yamamoto, Tomoya ; Masuda, Muneyuki ; Hirakawa, Naoya ; Nakamura, Kazumasa ; Shioyama, Yoshiyuki ; Umezaki, Toshiro ; Komune, Shizuo. / Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2005 ; Vol. 32, No. 6. pp. 803-807.
@article{9423004221364f6e9fe7d40418313d5e,
title = "Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer",
abstract = "The triple combination of 5-fluorouracil (5-FU), vitamin A and radiation (FAR therapy) has been effectively used to treat head and neck cancer. The biological anti-tumor effect of 5-FU depends on the activity of its metabolizing enzyme, dihydropyrimidine dehydrogenase (DPD). TS-1 is a novel oral DPD inhibitory fluoropyrimidine (DIF). To improve the anti-tumor effect of FAR therapy, we have applied TS-1 in place of 5-FU injection in the combination of Vitamin A and radiation (TAR therapy). In this study, we have examined the appropriate duration of TS-1 medication and the clinical efficacy and safety of TAR therapy. TS-1 was administered orally at a dose of 65 mg/m2 twice a day. Vitamin A (Retinol Palmitate: 50,000 U/day) was administered intra-musculary on each day of radiation. Radiation was given (1.5-2 Gy/day: 5 days/week) for 30-40 Gy. The levels were divided according to the length of TS-1 application as follows: level 1, 2 weeks; level 2, 3 weeks; level 4, 4 weeks. Grade 4 toxicity of anorexia was observed in one case of level 3. We decided that level 2 (3 weeks of TS-1 administration) was the appropriate length of TS-1 application. TAR therapy is a useful concurrent chemo-radiotherapy which might improve the response rate and QOL of patients with HNSCC.",
author = "Torahiko Nakashima and Yuichiro Kuratomi and Tomoya Yamamoto and Muneyuki Masuda and Naoya Hirakawa and Kazumasa Nakamura and Yoshiyuki Shioyama and Toshiro Umezaki and Shizuo Komune",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "32",
pages = "803--807",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer

AU - Nakashima, Torahiko

AU - Kuratomi, Yuichiro

AU - Yamamoto, Tomoya

AU - Masuda, Muneyuki

AU - Hirakawa, Naoya

AU - Nakamura, Kazumasa

AU - Shioyama, Yoshiyuki

AU - Umezaki, Toshiro

AU - Komune, Shizuo

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The triple combination of 5-fluorouracil (5-FU), vitamin A and radiation (FAR therapy) has been effectively used to treat head and neck cancer. The biological anti-tumor effect of 5-FU depends on the activity of its metabolizing enzyme, dihydropyrimidine dehydrogenase (DPD). TS-1 is a novel oral DPD inhibitory fluoropyrimidine (DIF). To improve the anti-tumor effect of FAR therapy, we have applied TS-1 in place of 5-FU injection in the combination of Vitamin A and radiation (TAR therapy). In this study, we have examined the appropriate duration of TS-1 medication and the clinical efficacy and safety of TAR therapy. TS-1 was administered orally at a dose of 65 mg/m2 twice a day. Vitamin A (Retinol Palmitate: 50,000 U/day) was administered intra-musculary on each day of radiation. Radiation was given (1.5-2 Gy/day: 5 days/week) for 30-40 Gy. The levels were divided according to the length of TS-1 application as follows: level 1, 2 weeks; level 2, 3 weeks; level 4, 4 weeks. Grade 4 toxicity of anorexia was observed in one case of level 3. We decided that level 2 (3 weeks of TS-1 administration) was the appropriate length of TS-1 application. TAR therapy is a useful concurrent chemo-radiotherapy which might improve the response rate and QOL of patients with HNSCC.

AB - The triple combination of 5-fluorouracil (5-FU), vitamin A and radiation (FAR therapy) has been effectively used to treat head and neck cancer. The biological anti-tumor effect of 5-FU depends on the activity of its metabolizing enzyme, dihydropyrimidine dehydrogenase (DPD). TS-1 is a novel oral DPD inhibitory fluoropyrimidine (DIF). To improve the anti-tumor effect of FAR therapy, we have applied TS-1 in place of 5-FU injection in the combination of Vitamin A and radiation (TAR therapy). In this study, we have examined the appropriate duration of TS-1 medication and the clinical efficacy and safety of TAR therapy. TS-1 was administered orally at a dose of 65 mg/m2 twice a day. Vitamin A (Retinol Palmitate: 50,000 U/day) was administered intra-musculary on each day of radiation. Radiation was given (1.5-2 Gy/day: 5 days/week) for 30-40 Gy. The levels were divided according to the length of TS-1 application as follows: level 1, 2 weeks; level 2, 3 weeks; level 4, 4 weeks. Grade 4 toxicity of anorexia was observed in one case of level 3. We decided that level 2 (3 weeks of TS-1 administration) was the appropriate length of TS-1 application. TAR therapy is a useful concurrent chemo-radiotherapy which might improve the response rate and QOL of patients with HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=21244469511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244469511&partnerID=8YFLogxK

M3 - Article

C2 - 15984520

AN - SCOPUS:21244469511

VL - 32

SP - 803

EP - 807

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -